| Literature DB >> 23705811 |
Danae Campos-Melo1, Cristian A Droppelmann, Zhongping He, Kathryn Volkening, Michael J Strong.
Abstract
BACKGROUND: Amyotrophic Lateral Sclerosis (ALS) is a progressive, adult onset, fatal neurodegenerative disease of motor neurons. There is emerging evidence that alterations in RNA metabolism may be critical in the pathogenesis of ALS. MicroRNAs (miRNAs) are small non-coding RNAs that are key determinants of mRNA stability. Considering that miRNAs are increasingly being recognized as having a role in a variety of neurodegenerative diseases, we decided to characterize the miRNA expression profile in spinal cord (SC) tissue in sporadic ALS (sALS) and controls. Furthermore, we performed functional analysis to identify a group of dysregulated miRNAs that could be responsible for the selective suppression of low molecular weight neurofilament (NFL) mRNA observed in ALS.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23705811 PMCID: PMC3668997 DOI: 10.1186/1756-6606-6-26
Source DB: PubMed Journal: Mol Brain ISSN: 1756-6606 Impact factor: 4.041
MiRNAs expressed in sALS but not in control spinal cord lysates
| 16-2* | 0.006 | 2.931744 |
| 146a* | 0.002 | 2.617606 |
| 508-5p | 0.018 | 1.689412 |
| 558 | <0.001 | 5.733327 |
MiRNAs expressed in control but not in sALS spinal cord lysates
| 520e | 0.034 | −1.743558 |
| 524-5p | 0.037 | −1.856280 |
| 548a-5p | 0.018 | −1.989360 |
| 606 | 0.027 | −1.949588 |
| 612 | 0.036 | −6.305046 |
| 624 | <0.001 | −3.218662 |
| 647 | 0.013 | −1.368500 |
MiRNAs expressed in both sALS and controls but up-regulated in sALS
| 373* | 0.004 | 3.646303 |
| 506 | 0.040 | 0.395549 |
| 518a-5p | 0.031 | 1.425218 |
| 518e* | 0.020 | 2.497707 |
| 551a | 0.009 | 0.989927 |
| 890 | 0.032 | 1.273212 |
Top networks and biological functions of miRNAs dysregulated in sALS
| Cellular development, nervous system development and function, tissue development | 3 | |
| Cellular assembly and organization, lipid metabolism, nucleic acid metabolism | 2 | |
| | ||
| | ||
| Reproductive system disease | 2.13E-03-2.13E-03 | 2 |
| Inflammatory response | 2.92E-03-2.92E-03 | 1 |
| Cancer | 6.81E-03-4.35E-02 | 3 |
| Hematological disease | 6.81E-03-6.81E-03 | 1 |
| Immunological disease | 6.81E-03-6.81E-03 | 1 |
| | ||
| Antigen presentation | 2.92E-03-2.92E-03 | 1 |
| Cell to cell signaling and interaction | 2.92E-03-2.92E-03 | 1 |
| | ||
| Hematological system development and function | 2.92E-03-2.92E-03 | 1 |
| Immune cell trafficking | 2.92E-03-2.92E-03 | 1 |
| Cancer, gastrointestinal disease, hepatic system disease | 26 | |
| Cancer, reproductive system disease, connective tissue disorders | 24 | |
| Cell death, cancer, cell cycle | 18 | |
| Cancer, reproductive system disease, gastrointestinal disease | 18 | |
| Reproductive system disease, cancer, cellular growth and proliferation | 11 | |
| | ||
| | ||
| Reproductive system disease | 4.31E-88-2.58E-03 | 93 |
| Inflammatory disease | 3.04E-47-4.99E-02 | 55 |
| Renal and urological disease | 3.04E-47-3.95E-03 | 52 |
| Cancer | 6.09E-41-4.40E-02 | 81 |
| Gastrointestinal disease | 1.44E-21-1.25E-02 | 48 |
| | ||
| Cellular development | 1.51E-07-4.40E-02 | 22 |
| Cellular growth and proliferation | 1.51E-07-4.99E-02 | 31 |
| Cell cycle | 2.16E-05-4.40E-02 | 11 |
| Cellular movement | 5.09E-04-4.99E-02 | 15 |
| Cell death | 7.84E-04-4.10E-02 | 12 |
| | ||
| Organismal development | 2.33E-11-6.61E09 | 7 |
| Connective tissue development and function | 2.16E-05-2.16E-05 | 4 |
| Hair and skin development and function | 8.96E-03-8.96E-03 | 1 |
| Nervous system development and function | 8.96E-03-8.96E-03 | 1 |
| Respiratory system development and function | 8.96E-03-3.54E-02 | 3 |
MiRNAs differentially expressed in sALS and controls, and predicted recognition elements (MRE) in NFL 3′UTR
| 23a | down | S/M/L | Conserved |
| 23b | down | S/M/L | Conserved |
| 30a | down | S/M/L | Conserved |
| 30b | down | S/M/L | Conserved |
| 146a* | up | M/L | Not conserved |
| 192 | down | M/L | Conserved |
| 193a-5p | down | M/L | Not conserved |
| 215 | down | M/L | Conserved |
| 524-5p | down | L | Not conserved |
| 556-5p | down | M/L | Not conserved |
| 582-3p | down | S/M/L | Not conserved |
Figure 1Illustration of the sequence alignment of the NFL mRNA 3′UTRs of different species. (A) Percentages of sequence identity between Homo sapiens and other mammals are indicated. (B) MREs within the different NFL mRNA 3′ UTRs. Note that not all miRNAs have MREs within the three NFL 3′UTRs reported (−S, -M and –L).
Figure 2A pool of miRNAs dysregulated in sALS regulates the activity of a reporter linked to NFL 3′UTR. Reporter gene assay was performed transfecting HEK293T cells with pre-miRNAs and a reporter construct expressing firefly luciferase coupled to NFL 3′UTR-S (white bar), -M (grey bar) or -L (black bar). The results of firefly luciferase activity were normalized with Renilla reporter luciferase activity and with the effect of each miRNA on the luciferase mRNA alone (pmirGLO vector control). Data are expressed as relative change and show positive values as up-regulation and negative values as down-regulation. Experiments were performed in triplicate. Result are shown as mean ± SEM (t-test: *** = p < 0.001; ** = p < 0.01, relative to the pmirGLO vector control). Note that not all miRNA have predicted interaction sites in all lengths of NFL 3′UTR, only data for which a predicted site is present are shown. In addition, only miRNAs with correlation among the results of the reporter gene assay and the expression observed in sALS are presented.
Figure 3MiR-146a*, miR-524-5p and miR-582-3p regulate the expression of NFL mRNA 3′UTR. Relative quantitative RT-PCR was performed after the co-transfection of HEK293T cells with pre-miRNAs whose function was correlated with the differential expression observed sALS and a reporter construct expressing firefly luciferase coupled to NFL 3′UTR-S (white bar), -M (grey bar) or -L (black bar). Firefly luciferase was normalized to Renilla luciferase, the impact of each miRNA on the luciferase mRNA without NFL 3′UTR (pmirGLO vector control), and the effect of miR-let-7a (miRNA control) on the luciferase mRNA to obtain the specific effect on the NFL mRNA 3′UTR. Data are expressed as relative mRNA level change and show up-regulation as positive values and down-regulation as negative values. Experiments were performed in triplicate. Result are shown as mean ± SEM (t-test: *** = p < 0.001; ** = p < 0.01, relative to the pmirGLO vector control). Note that only results for those miRNAs that showed RT-PCR results in agreement with the reporter gene assay data are presented.
Figure 4Mutations in the recognition elements of miR-146a*, miR-524-5p and miR-582-3p reveal a direct regulation of the miRNA on luciferase transcripts coupled to the NFL 3′UTR. (A) Mutants of MREs within the NFL 3′UTR. Only the first two nucleotides of the 3′ end of each MRE were mutated (arrows) preventing broad changes in the NFL 3′UTR secondary structure. (B) ΔGs of wild type (WT) and mutant (Mut) MREs within NFL 3′UTR. (C) Reporter gene assay performed with mutant NFL 3′UTRs. The results of firefly luciferase activity were normalized with Renilla reporter luciferase activity and the effect of each miRNA on the luciferase mRNA alone (pmirGLO vector control). Data are expressed as relative change and show up-regulation as positive values and down-regulation as negative values. Experiments were performed in triplicate. Result are shown as mean ± SEM (t-test: *** = p < 0.001; * = p < 0.05, relative to the pmirGLO vector control). All the NFL 3′UTR mutants showed a significant decrease in the effect of each miRNA compared with the wild type.
Patient demographics for SC tissues included in this study
| Control | F | - | 53 | - | Cardiac transplant, pneumonia, rejection |
| Control | M | - | 68 | - | Cancer |
| Control | F | - | 62 | - | Ischemic heart disease, myocardial infarct |
| ALS | F | 47 | 49 | Bulbar | Respiratory failure |
| ALS | F | Unknown | 41 | Bulbar | Respiratory failure |
| ALS | M | 55 | 61 | Unknown | Pneumonia |
| ALS | M | 40 | 44 | Spasticity | Unknown |
| ALS | M | 64 | 67 | Upper limb, weakness | Respiratory failure |
-: Not applicable.